Comparison · NCT00359801-c14abf12
Exubera® vs Non-Exubera®: All-cause Mortality: Number of Deaths
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Exubera® vs Non-Exubera®: All-cause Mortality: Number of Deaths. Trial comparisons, record NCT00359801-c14abf12. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00359801-c14abf12
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0122 | 0.00697 | 0.0211 | wilson | |
| Risk in group 2 | 0.0091 | 0.00479 | 0.0172 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00306 | -0.00657 | 0.013 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.34 | 0.565 | 3.16 | log | |
| Odds ratio, group 1 over group 2 | 1.34 | 0.562 | 3.2 | log | |
| Number needed to treat, for one more participant with the outcome on Exubera® than on Non-Exubera® | 327 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Exubera® | Exubera® plus usual diabetes care | 12 | 987 | OG000 |
| Group 2 | Non-Exubera® | Usual diabetes care | 9 | 989 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- All-cause Mortality: Number of Deaths
- Description
Endpoint committee adjudicated the endpoint based on review of medical and hospital records, and results were classified using standard criteria (confirmation of deaths by blinded adjudicator(s) through medical records or death certificates). Patients meeting the endpoint All Cause Mortality after adjudication by the endpoint committee.
- Time frame
- Baseline through End of Study
- Population
- FAS
Source ClinicalTrials.gov
Trial
- Title
- Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular Safety
- NCT number
- NCT00359801
- Phases
- PHASE4
- Conditions
- Diabetes Mellitus
- Interventions
- Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care, Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care
- Lead sponsor
- Pfizer
- Results first posted
- 2010-01-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00359801?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00359801-c14abf12